PMID- 10499619
OWN - NLM
STAT- MEDLINE
DCOM- 19991122
LR  - 20061115
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 5
IP  - 9
DP  - 1999 Sep
TI  - Patterns of p53 gene mutations in head and neck cancer: full-length gene
      sequencing and results of primary radiotherapy.
PG  - 2455-63
AB  - p53 gene alterations are common in head and neck cancers, but their prognostic
      value has not been clearly established. Despite evidence in other cancers that
      sequencing of the entire p53 coding region provides prognostic information,
      full-length p53 gene sequencing has rarely been performed in head and neck
      cancers. In this study, p53 was assessed in a series of 42 pretreatment biopsies 
      from patients with laryngeal carcinomas by full-length gene sequencing and by
      immunohistochemistry (IHC). Associations among p53 genotype, protein expression, 
      and local recurrence were assessed in 35 irradiated patients followed for a
      minimum of 5 years. DNA was extracted from formalin-fixed, paraffin-embedded
      biopsies, and exons 2-11 of the p53 gene were individually amplified by PCR and
      then directly sequenced. IHC was performed to detect mutant and wild-type p53
      protein using the DO7 monoclonal antibody. p21 protein expression was assessed
      using the EA1 monoclonal antibody. Twenty genetic alterations were observed in 42
      tumors (48%). Four of these alterations (20%) occurred outside exons 5-8. There
      was a significant association between p53 gene and protein status (chi2 = 4.18, P
      = 0.04), although the correlation was weak (phi coefficient = -0.327). Although
      local relapse following radiation was significantly associated with nodal status,
      no correlations were observed between p53 status (gene or IHC) and local
      recurrence following radiation therapy, based on the Kaplan-Meier method. These
      results show that p53 mutations are common in laryngeal carcinomas and that a
      proportion occur outside traditionally examined regions. The lack of correlation 
      between p53 status and local control suggests that this marker is not as powerful
      as traditional prognostic factors, such as lymph node status.
FAU - Saunders, M E
AU  - Saunders ME
AD  - Faculty of Dentistry, University of Toronto, Ontario, Canada.
FAU - MacKenzie, R
AU  - MacKenzie R
FAU - Shipman, R
AU  - Shipman R
FAU - Fransen, E
AU  - Fransen E
FAU - Gilbert, R
AU  - Gilbert R
FAU - Jordan, R C
AU  - Jordan RC
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for
      Cancer Research
JID - 9502500
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Aged
MH  - Base Sequence
MH  - DNA Mutational Analysis
MH  - Exons
MH  - Female
MH  - Follow-Up Studies
MH  - *Genes, p53
MH  - Humans
MH  - Immunohistochemistry
MH  - Laryngeal Neoplasms/chemistry/*genetics/pathology/*radiotherapy
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Prognosis
MH  - Sequence Analysis, DNA
MH  - Sequence Homology, Nucleic Acid
MH  - Tumor Suppressor Protein p53/biosynthesis
EDAT- 1999/09/28 00:00
MHDA- 1999/09/28 00:01
CRDT- 1999/09/28 00:00
PHST- 1999/09/28 00:00 [pubmed]
PHST- 1999/09/28 00:01 [medline]
PHST- 1999/09/28 00:00 [entrez]
PST - ppublish
SO  - Clin Cancer Res. 1999 Sep;5(9):2455-63.